Australasian Journal of Dermatology最新文献

{"title":"Systematic Review and Meta-Analysis of the Efficacy and Risk of Adverse Events of Dupilumab in the Treatment of Prurigo Nodularis.","authors":"Hicham Titou, Younes Elkhachine, Jalal El Benaye","doi":"10.1111/ajd.14534","DOIUrl":"https://doi.org/10.1111/ajd.14534","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 5","pages":"312-318"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes Towards the Use of Artificial Intelligence in Dermatology: A Survey of Australian Dermatologists.","authors":"Brad Partridge, Monika Janda, Nicole Gillespie, Carina Vasconcelos Silva, Chris Arnold, Lisa Abbott, Tony Caccetta, H Peter Soyer","doi":"10.1111/ajd.14524","DOIUrl":"10.1111/ajd.14524","url":null,"abstract":"<p><strong>Background/objectives: </strong>This study explored the views of dermatologists in Australia on the use of Artificial Intelligence (AI) in dermatology.</p><p><strong>Method: </strong>Fellows and Trainees of the Australasian College of Dermatologists (ACD) were invited to participate in an anonymous online survey, resulting in a sample of 122 completed surveys (response rate 16.2%).</p><p><strong>Results: </strong>Although 44% have used AI in their dermatology practice, only a minority are using AI regularly for clinical (12%) or administrative purposes (17%). A key barrier is trust, with most (69%) participants either unwilling or unsure about trusting AI for supporting the diagnosis of skin cancer. Participants identified accuracy and information on datasets, limitations, benefits, and the purpose of AI as important for trust. 52% want AI accuracy to be equivalent to or superior to the best dermatologist if it is used for clinical diagnosis. Participants perceived a range of benefits and risks of AI, with key risks around accuracy and divestment of AI to tech companies, and key benefits being reduction of monotonous tasks and improved patient access. Few (10%) are concerned about AI replacing dermatologists even though almost half (47%) expect key aspects of dermatology work will be performed by AI.</p><p><strong>Conclusions: </strong>Dermatologists in Australia are at an early stage of integrating AI into practice, with most wary or unsure about the accuracy of currently available AI tools for diagnostic purposes. Developing workflows that are acceptable to clinicians may require knowledge outreach from Dermatology Colleges, such as the ACD, to help clinicians develop well informed views on AI.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"e279-e286"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"A Rare Case of Bilateral Symmetrical Broad-Based Acquired Ungual Fibrokeratomas\".","authors":"","doi":"10.1111/ajd.14527","DOIUrl":"10.1111/ajd.14527","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"319"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs Micrographic Surgery for Basal Cell Carcinoma: Predictive Factors for Increased Stages and Relative Defect Sizes.","authors":"Subashini Gnanendran, Marra Aghajani, James Elhindi, Simon Lee, Gilberto Moreno Bonilla","doi":"10.1111/ajd.14535","DOIUrl":"10.1111/ajd.14535","url":null,"abstract":"<p><p>Keratinocyte cancers (KCs), including basal cell carcinomas (BCCs), are the most common cancers in Australia. While Mohs micrographic surgery (MMS) is the gold standard treatment, it can be resource intensive, particularly for cases requiring multiple stages. This study aimed to identify predictors of increased MMS stages and a greater tumour-to-defect size discrepancy in head and neck BCC. A retrospective analysis of the Mohs Electronic Database at the Skin Hospital's Westmead and Darlinghurst sites in Sydney, Australia was conducted from October 2012 to December 2022, including 18,346 BCC cases. The main outcomes were the number of MMS stages and the relative defect size, with covariates including patient age, sex, tumour characteristics and Mohs specialist factors. Older patients required more stages (1.65 vs. 1.90; p < 0.01) and had larger relative defect sizes (2.10 vs. 2.90; p < 0.01). Larger tumours required more stages (1.69 vs. 1.94; p < 0.01), while smaller tumours had disproportionately larger relative defects (5.94 vs. 2.08; p < 0.01). Nodular BCC required fewer stages (1.63; p < 0.01) and had the smallest defects (2.11; p < 0.01). Notably, superficial BCCs required a similar number of MMS stages as traditionally aggressive subtypes. Tumours of the ear, eye and nose required more stages than other cosmetic units (2.05, 2.02, 1.94; p < 0.01). Increased Mohs experience reduced the number of stages (2.18 vs. 1.83; p = 0.03) and relative defect sizes (3.49 vs. 2.50; p < 0.01). Patient age, tumour size, subtype, cosmetic unit and Mohs specialist experience influence MMS stages and relative defect sizes in head and neck BCC. Recognising these factors can enhance surgical planning, personalise treatment strategies and improve patient outcomes.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"258-267"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis.","authors":"Mizuho Namba, Mika Matsumoto, Naoya Saito, Atsuko Kimura, Chihiro Sagara, Daiki Rokunohe, Eijiro Akasaka","doi":"10.1111/ajd.14541","DOIUrl":"10.1111/ajd.14541","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"e314-e315"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Using Oral Sodium Cromoglycate for Controlling Epidermolysis Bullosa-Related Pruritus.","authors":"Sera Sarsam, Annabel Stevenson, Dédée F Murrell","doi":"10.1111/ajd.14530","DOIUrl":"10.1111/ajd.14530","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"309-311"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2 Expression and Its Correlation With Clinicopathological Features and Prognosis in Extramammary Paget's Disease: A Systematic Review and Meta-Analysis.","authors":"Sandra Ramírez-Clavijo, Daniel F Mendivelso-González, Ricardo Monroy, Jairo de la Peña, Wilson Rubiano, Ana Monsalve-Lancheros, Rafael Parra-Medina","doi":"10.1111/ajd.14490","DOIUrl":"10.1111/ajd.14490","url":null,"abstract":"<p><strong>Background: </strong>Extramammary Paget's disease (EMPD) is a neoplastic condition primarily in the anogenital region. A subset of cases exhibits HER2 expression, generally associated with poor prognosis. This paper aimed to systematically explore the potential correlation between HER2 expression, clinicopathological features and prognosis in EMPD.</p><p><strong>Methods: </strong>A systematic search (1990-2023) was conducted via BVS, Embase, Google Scholar, PubMed, Scopus and Web of Science. A meta-analysis with odds ratios (ORs) and confidence intervals (CIs) was performed.</p><p><strong>Results: </strong>A total of 954 patients from 16 studies were included. The median age at diagnosis was 70.3 years, with the majority being men (71.8%). The penoscrotal area was the most common site of presentation. HER2 positivity was 25.6%, and the HER2-low proportion was 38.5%. Positive HER2 expression was correlated with EMPD dermal invasion (OR = 4.01, 95% CI: 2.11-7.62) and the presence of lymph node metastasis (OR = 3.84, 95% CI: 1.59-9.30), but not with the presence of secondary malignancies or the female gender. Gene expression among patients with IHC 2+ and 3+ was correlated with tumour dermal invasion (pooled OR = 6.43, 95% CI: 1.23-33.57). No correlation was found between HER2-low expression and dermal invasion, lymph node metastasis or the presence of secondary primary malignancies.</p><p><strong>Conclusion: </strong>HER2 was expressed in a significant proportion in EMPD with significant correlations, suggesting its potential role as a prognostic biomarker.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"279-288"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichen Planus Following COVID-19 Infection and Vaccination. Matched Case-Control Study.","authors":"Paolo Giacomo Arduino, Alexey Kubanov, Anna Vlasova, Andrey Martynov, Stefano Petti","doi":"10.1111/ajd.14522","DOIUrl":"10.1111/ajd.14522","url":null,"abstract":"<p><strong>Background: </strong>New-onset lichen planus (LP) development following COVID-19 infection/vaccination is reported. Since case series cannot be used to study exposure-outcome associations, we designed this matched case-control study to investigate whether COVID-19-related events and de novo LP are associated.</p><p><strong>Methods: </strong>Patients with histologically confirmed LP, newly diagnosed at the National Research Center of Dermato-Venereology of Moscow (September 2020-December 2022), were considered. Sex/age/ethnicity-matched controls attending the same Center in the same period for consultations on conditions unrelated to LP were selected. Cases/controls with known LP trigger factors were excluded. COVID-19-related events were: symptomatic COVID-19 (PCR-confirmed), and COVID-19 vaccination (viral vector vaccine) occurred ≤ 1 month before the visit at the Center. The association between COVID-19-related events and LP was assessed with conditional (Mantel-Haenszel method) and unconditional (logistic regression analysis adjusted for sex, age, and smoking) analyses. Subgroup analysis, with COVID-19 infection and vaccination treated separately, and sensitivity analysis on another group of patients with suspected LP, not confirmed histologically, were also made.</p><p><strong>Results: </strong>Fifty-five case-control pairs were considered. Mean age (51 years), sex (56.4% females) and ethnicity (100% whites) distributions were the same in both groups. Conditional and unconditional odds ratios resulted 7.50 (95% Confidence Interval -95CI, 1.72-32.80), 4.45 (95CI, 1.63-12.15), respectively (p < 0.05). Subgroup analysis confirmed the association between symptomatic infection and LP, while sensitivity analysis corroborated the results of the primary analysis.</p><p><strong>Conclusions: </strong>This observational study, reporting a strong significant association between COVID-19 infection/vaccination and de-novo LP, suggests that COVID-19-related events, especially infection, could act as LP trigger factors.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"289-295"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid.","authors":"Bronte Jeffrey, Mark Schifter, Elizabeth Arena, Emily Sullivan, Stephanie Rose, David Joo, David Campbell, Suzanne Culican, David McDonald, Ming Wei Lin","doi":"10.1111/ajd.14523","DOIUrl":"10.1111/ajd.14523","url":null,"abstract":"<p><strong>Background: </strong>Mucous membrane pemphigoid (MMP) has a broad range of clinical manifestations, from relatively benign self-limiting oral lesions to significant scarring (cicatrizing) of the oral, nasal and ocular tissues with severe functional impairment and morbidity. European Guidelines recommend rituximab as only second- or third-line therapy, based on the extent/severity of the disease; however, there are no established clinical or serological markers that are predictive of severe disease warranting the use of agents such as rituximab.</p><p><strong>Methods: </strong>Retrospective cross-sectional cohort study of patients who met the following criteria: (1) biopsy confirmed MMP; (2) required a steroid-sparing immunosuppressant therapy, that is, mycophenolate and/or rituximab and (3) at least 6 months of clinical monitoring. The primary end point was complete or partial remission.</p><p><strong>Results: </strong>Of the 45 patients who met the criteria, 12 (27%) had sustained remission with mycophenolate. Thirty-three (73%) patients had either relapsed or were refractory to mycophenolate and, therefore, were treated with rituximab. Of those who received rituximab, 97% achieved a complete remission after a single course (1 g given intravenously on Days 1 and 14), but 24% needed repeat treatment. The detection rates of key circulating antibodies, namely skin basement membrane antibodies (SBMA), BP180/230, collagen VII and laminin 332, were low and did not identify those patients refractory to mycophenolate. Adverse reactions, including infectious complications, were minimal in both patient groups.</p><p><strong>Conclusion: </strong>In our study of mostly localised mucosal MMP patients, there was an excellent response to a single course of treatment with rituximab, with durable remission and no major adverse complications.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":"e271-e278"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Metastasis or Skipped Nodal Metastasis?","authors":"Niranjan Bista, Benjamin Philip, Patrick Shenjere, Deemesh Oudit","doi":"10.1111/ajd.14537","DOIUrl":"https://doi.org/10.1111/ajd.14537","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 5","pages":"e321-e323"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}